Cash-pay direct-to-consumer GLP-1 longitudinal treatment records

Name: Cash-pay direct-to-consumer GLP-1 longitudinal treatment records: repeat refill-visit encounters for established patients on semaglutide or tirzepatide, each capturing self-reported weight-loss progress, medication tolerance, side-effect review, dose and plan adjustments, prescription renewal or discontinuation decisions, and partner-pharmacy compounded-versus-brand dispensing routing
Creator: Omnia TeleHealth

OMNIA TELEHEALTHManage supplier listing

Cash-pay direct-to-consumer GLP-1 longitudinal treatment records: repeat refill-visit encounters for established patients on semaglutide or tirzepatide, each capturing self-reported weight-loss progress, medication tolerance, side-effect review, dose and plan adjustments, prescription renewal or discontinuation decisions, and partner-pharmacy compounded-versus-brand dispensing routing

Open buyer room →

Sample

Brickroad customers

Sample this dataset before you buy it.

Your sourcing agent asks Omnia TeleHealth and files the sample in your catalog — private to you.

Start 7-day trialNothing is charged until the trial ends.

Coverage

Universe, instruments and categories.

Industry: Health Care ServicesPharmaceuticals
Instruments: equities
Categories: Alternative
Regions: US
Sample tickers: NVOLLYHIMSRKTWBACVS

Dataset card

Type: not stated
Format: Unstructured-to-semi-structured clinical encounter notes from virtual visits (chief complaint, tolerance, side-effect narrative, plan) within a telehealth EHR, with a thin structured overlay of medication, dose, weight and renewal decision fields; no published API, export or data-platform surface on the site
Volume: Small and finite: estimate low thousands to tens of thousands of total encounter notes across the practice's life (single founding provider, cash-pay at $69 per visit), each carrying a weight, tolerance, side-effect and decision entry. The genuinely interesting slice is narrow but hard to obtain elsewhere — a documented compounded-GLP-1 treatment cohort with renewal and discontinuation reasons recorded in free text
Users: N/A as a platform metric — a telehealth practice that serves patients rather than users. Population proxy: a single-provider cash-pay practice at $69 per refill visit implies a patient book plausibly in the low hundreds to low thousands, not a scalable app user base
History: 3 years
Update frequency: not stated
Growth: Active but structurally small — service pages maintained with current medical-review dating, an established refill pathway layered on top of an existing weight-loss consultation funnel, and a partner-pharmacy relationship for compounded supply. Growth is capped by single-clinician capacity
Launched: not stated
Delivery: not stated
Entity mapping: not stated
Sample: not stated
Point-in-time: not stated
Licence: not stated

supplier index read from their site

Omnia TeleHealth has not added their own details yet. Not yet on file:

Dataset
Data dictionary
Coverage
Provenance
Rights & data handling